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Processing of Some Antigens by the Standard
Proteasome but Not by the Immunoproteasome
Results in Poor Presentation by Dendritic Cells
20S core of this complex has the shape of a barrel made
of four rings. The two outer rings are identical and each
is composed of seven distinct a subunits. The two inner
rings are also identical. Each contains seven different
b subunits, which surround a central chamber where
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B-1000 Brussels by their IFNg-inducible homologs, LMP2 (b1i), MECL1
(b2i), and LMP7 (b5i), respectively. Historically, the loca-Belgium
tion of LMP2 and LMP7 genes in the MHC class II locus
was one of the first clues suggesting their involvement
in antigen presentation (Glynne et al., 1991; Kelly et al.,Summary
1991; Martinez and Monaco 1991; Ortiz-Navarrete et al.,
1991). This was further investigated in mice lacking oneBy stimulating human lymphocytes with an autologous
renal carcinoma, we obtained CTL recognizing an anti- of these inducible subunits. Mice deficient for LMP7
were found to have an impairment in the presentationgen derived from a novel, ubiquitous protein. The CTL
failed to lyse autologous EBV-transformed B cells, of certain antigens and a reduced surface MHC class
I expression, possibly reflecting a defective supply ineven though the latter express the protein. This is due
to the presence in these cells of immunoproteasomes, antigenic peptides (Fehling et al., 1994). LMP2-knockout
mice, although expressing normal levels of surface MHCwhich, unlike standard proteasomes, cannot produce
the antigenic peptide. We show that dendritic cells class I, had a reduced CD81 T cell number and a poor
response to a viral epitope (Van Kaer et al., 1994). Inalso carry immunoproteasomes and fail to present this
antigen. This may explain why the relevant CTL escape vitro studies performed with viral epitopes also showed
that the proteasome equipped with LMP2, LMP7, andthymic deletion and are not regularly activated in the
periphery. Lack of cleavage by the immunoprotea- MECL1 is more efficient in processing a number of anti-
genic peptides (Cerundolo et al., 1995). For this reason,some was also observed for melanoma differentiation
antigen Melan-A26-35/HLA-A2, currently used for antitu- it was called ªimmunoproteasome,º as opposed to the
moral vaccination. For immunization with such anti- constitutively expressed standard proteasome. When
gens, proteins should be less suitable than peptides, tested in vitro on fluorogenic substrates, the catalytic
which do not require proteasome digestion in dendritic activity of the immunoproteasome is characterized by
cells. a reduced cleavage after acidic amino acids and an
increase in the cleavage after hydrophobic and basic
residues. As the latter residues are those most fre-Introduction
quently found at the C terminus of peptides efficiently
binding to MHC class I molecules, this reinforced theThe proteasome is a large multicatalytic protease com-
notion that the immunoproteasome is more efficientplex found in the nucleus and cytoplasm of eukaryotic
than the standard proteasome for antigen presentationcells (for a review see Rock and Goldberg, 1999). The
(Rock and Goldberg, 1999).
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immunoproteasome is not capable of processing someeynde@licr.ucl.ac.be).
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standard proteasome. We also show that the immuno-
proteasome is constitutively expressed in mature den-
dritic cells, which therefore cannot present those pep-
tides.
Results
A CTL Raised against an Autologous Renal Carcinoma
Recognizes a Ubiquitous Antigen
Cytolytic T lymphocyte (CTL) clone 381/84 was gener-
ated by stimulating blood lymphocytes from a cancer
patient with the BB64-RCC autologous renal carcinoma
cell line transfected with costimulatory molecule B7-1.
Recognition of the tumor cells by this CTL clone was
evaluated either by a lysis assay (Figure 1A) or by mea-
suring the amount of tumor necrosis factor (TNF) re-
leased by the CTL upon contact with the tumor cells
(Figure 1B). This CTL clone, which was restricted by
HLA-B51, recognized both autologous and allogeneic
B511 tumor cells as well as B511 normal cells such
as fibroblasts or normal kidney cells (Figure 1B). We
concluded that the target antigen was a ubiquitous self-
antigen.
We identified the gene encoding this antigen by
screening for CTL recognition cells transfected with a
cDNA library derived from BB64-RCC cells and with an
HLA-B51 cDNA, as previously described (GueÂ guen et
al., 1998). We named this novel gene RU1 (Renal Ubiqui-
tous). Its sequence is identical in the tumor cells and in
autologous normal cells. It is expressed in all cell lines
and normal tissue samples tested by RT±PCR, including
the thymus (Figure 2A). It codes for a protein of 866
amino acids. Nonapeptide VPYGSFKHV, which corre-
sponds to residues 34±42 of the protein, is efficiently
recognized by CTL clone 381/84 when pulsed onto HLA-
B51 cells (Figure 1C).
Figure 1. Characterization of CTL Clone 381/84 and IdentificationLack of Recognition of Autologous EBV-B
of Its Target Antigen
Lymphocytes by the anti-RU1 CTL
(A) The following target cells were tested in a standard 4 hr chromiumDespite the ubiquitous expression of RU1, we consis-
release assay: BB64-RCC, the autologous tumor line; BB64-RCC-
tently observed that an autologous EBV-transformed B B7, the autologous tumor line transfected with costimulatory mole-
cell line (BB64-EBV) was not recognized at all by CTL cule B7-1; BB64-EBV, autologous B lymphocytes transformed with
the Epstein-Barr virus; and K562, natural killer target cell line.381/84 (Figure 1A). This was measured in the lytic assay,
(B) CTL activation was followed by measuring the production ofthe TNF assay being inapplicable to EBV-B cells be-
tumor necrosis factor (TNF) after stimulation with the indicated cells.cause they produce high amounts of TNF. This lack
LB4-MEL and LB39-MEL are two allogeneic melanoma lines ex-of recognition did not result from the absence of RU1
pressing HLA-B51. LB37 fibroblasts were derived from an HLA-B51
messenger RNA in EBV-B cells, since BB64-EBV was individual. The normal kidney cell line (LB2043-PTEC) was derived
positive by RT±PCR (Figure 2A). Moreover, a Western from the proximal tubule epithelium of a normal kidney. It was tran-
siently transfected with a plasmid construct encoding HLA-B*5101.blot carried out with a specific antiserum revealed identi-
TNF production was measured after 20 hr.cal amounts of RU1 protein in the tumor cells and EBV-B
(C) Recognition of peptide VPYGSFKHV by CTL 381/84. Variouscells (Figure 2B). We also ascertained that the sequence
concentrations of the synthetic peptide were pulsed on chromium-encoding the peptide region was identical in the EBV-B
labeled BB64-EBV cells, and CTL were added at an effector/target
cells and in the tumor (Figure 3). ratio of 10. Chromium release was measured after 4 hr. Octamers
Because EBV-B cells usually express high amounts corresponding to truncation at either the N or the C terminus were
tested similarly and were not recognized (data not shown).of HLA class I molecules, we considered the possibility
that they could trigger a killer inhibitory receptor that
would be present on the CTL and thereby escape CTL
recognition (Ikeda et al., 1997). This was excluded, how- Lack of Processing of the RU1 Peptide
by the EBV-B Cell Proteasomesever, by the fact that BB64-EBV were recognized after
being pulsed with the synthetic peptide (Figure 1C). The processing of the RU1 peptide depends on the
proteasome, because lactacystin, which specificallyTaken together, these results suggested that the tumor
cells and the EBV-B cells differed in their ability to pro- inhibits the proteasome, completely prevents the recog-
nition of BB64-RCC cells by CTL 381/84 (data notcess the antigenic peptide.
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Figure 3. Sequence of the Peptide-Coding Region of the RU1 Gene
Derived from BB64-RCC or BB64-EBV Cells
The autoradiography shows the sequence ladder of the relevant
region sequenced either from the RU1 cDNA initially isolated from
BB64-RCC cells or from a 636 bp product obtained by PCR amplifi-
cation of cDNA from BB64-EBV cells using primers SMO18 and
SMO19. Sequencing was performed using an RU1-specific primer
located on the reverse strand (nucleotides 624±641).
cleavage differences were observed in the cleavages
Figure 2. Expression of Gene RU1 after threonine 44 and valine 42, which were both much
(A) RT±PCR analysis of the expression of RU1 mRNA in various cell more efficient with the proteasomes isolated from the
lines and tissue samples. The renal carcinoma line was LB1047- tumor cells (Figures 4C and 4D). Interestingly, the cleav-
RCC and the bladder carcinoma line was LB831-BLC. BB64-RCC age after valine 42 generates the proper C terminus of
cells were treated with IFNg for 10 days where indicated. Dendritic
the antigenic peptide. In contrast, the cleavage aftercells were prepared as indicated in Figure 7. RT±PCR were per-
phenylalanine 39, which destroys the epitope, wasformed on total RNA except for dendritic cells and thymus, for which
slightly more efficient with the proteasome from thepoly(A)1 RNA was used.
(B) Western blot analysis of the expression the RU1 protein. A rabbit EBV-B cells (Figures 4C and 4D). Fragments with the
antiserum raised against a C-terminal peptide of the RU1 protein proper N terminus were not detected in our study. This
was used to stain a Western blot loaded with the indicated amounts is in line with the notion that the generation of the N
of proteins from cell lysates of BB64-RCC, BB64-EBV, or BB64-
terminus of certain antigenic peptides does not dependRCC treated for 8 days with IFNg. The protein was revealed by
on the proteasome but can result from further trimmingchemiluminescence after incubation with an anti-rabbit secondary
either in the cytosol or the endoplasmic reticulum (Be-antibody coupled to horseradish peroxidase.
ninga et al., 1998; Stoltze et al., 1998). We conclude that
the proteasomes isolated from the EBV-B cells do not
efficiently produce the antigenic peptide, most likely dueshown). Proteasomes from both the tumor cells and the
to an inefficient cleavage at the C terminus and a slightlyEBV-B cells were purified and used to digest in vitro
higher cleavage within the epitope sequence.peptide RU129-47, a 19±amino acid peptide encom-
passing the epitope, to see whether they would differ
in their ability to cleave this model precursor of the Lack of Processing Is Due to the Presence
of the Immunoproteasomeantigenic peptide. The peptide digests were then pulsed
onto HLA-B51-positive cells and tested for recognition EBV-transformed B cell lines have been shown to ex-
press the immunoproteasome constitutively (Frisan etby CTL 381/84. As shown in Figure 4A, the 30, 60, and
120 min digests obtained with the proteasomes isolated al., 1998). We confirmed by Western blot that LMP2 and
LMP7 were present at high levels in the proteasomesfrom tumor cells were recognized by the CTL, whereas
the corresponding digests obtained with proteasomes purified from BB64-EBV and were absent in the protea-
somes isolated from BB64-RCC (Figure 5). The levelsfrom EBV-B cells produced little or no recognition.
To characterize the cleavage differences, the peptides of LMP2 and LMP7 in BB64-EBV were similar to those
found in BB64-RCC cells treated for 10 days with IFNg.present in the digests were separated by reverse-phase
HPLC, identified by online electrospray ionization/mass We reasoned that if the lack of recognition of BB64-
EBV cells by CTL 381/84 was due to their constitutivespectrometry (ESI/MS), and quantified by online UV ab-
sorption, as previously described (Ayyoub et al., 1998). expression of the immunoproteasome, then tumor cells
should also lose expression of the epitope after pro-An overview of all the detected fragments is shown in
Figure 4B. The kinetics of degradation of the precursor longed treatment with IFNg. BB64-RCC tumor cells were
treated with IFNg for 2, 4, or 6 days before being testedpeptide indicated that the overall activity of the tumor
proteasomes was higher than that of the EBV-B cell for recognition by CTL 381/84. As shown in Figure 6A,
we observed a progressive loss of CTL recognition,proteasomes (Figures 4C and 4D). The most striking
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Figure 4. In Vitro Digestion of Precursor Peptide RU129-47 with Proteasomes Isolated from BB64-RCC, BB64-EBV, or BB64-RCC Treated for
10 Days with IFNg
(A) Stimulation of CTL 381/84 with peptide digests pulsed onto 293-EBNA cells transfected with HLA-B*5101. TNF production was measured
after 20 hr. Standard errors of the mean (SEM) are shown.
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with IFNg and confirmed that they contained LMP2 and
LMP7 (Figure 5). The activity of these proteasomes to
digest the RU1 precursor peptide was very similar to
that of the proteasomes isolated from EBV-B cells, with
a low overall activity on the precursor peptide, an ab-
sence of cleavage after threonine 44 and valine 42, and
a predominant cleavage after phenylalanine 39 (Figures
4C and 4D). There was a complete lack of recognition
of the peptide digests by CTL 381/84 (Figure 4A). We
conclude that the lack of recognition of both EBV-B cells
and IFNg-treated tumor cells results from the replace-
ment of the standard proteasome by the immunopro-
teasome.
In addition to inducing LMP2, LMP7, and MECL1 ex-
pression, IFNg is known to induce expression of PA28,
which appears to increase the activity of the proteasomeFigure 5. Presence of the Immunoproteasome in BB64-EBV Cells
(Tanaka and Kasahara, 1998). However, it is unlikely thatand BB64-RCC Cells Treated with IFNg for 10 Days
PA28 is responsible for the difference we detected inPolyclonal antibodies directed against LMP7 and LMP2 were used
to stain a Western blot loaded with 0.8 mg of proteasome isolated vitro, since the proteasomes that were isolated con-
from the indicated cells by immunoprecipitation. Staining of consti- tained exclusively the 20S core. To demonstrate directly
tutive subunit a2 was performed to control the amount of protea- that LMP2, LMP7, and MECL1 were responsible for the
somes loaded. The proteins were revealed by chemiluminescence. effect detected after IFNg treatment, we transfected
BB64-RCC cells with plasmid constructs encoding
these three subunits. We obtained a stable transfectantwhich was almost complete after 6 days of IFNg treat-
that expressed LMP2, LMP7, and MECL1. There was ament. Although already visible after 2 days, the effect
marked decrease in the recognition of this transfectantwas only maximal after 6 days, presumably due to the
by CTL 381/84, whereas its ability to stimulate the CTLtime required for the exchange of proteasome subunits
after addition of the relevant synthetic peptide was theand also for the clearance of the preexisting antigenic
same as that of BB64-RCC (Figure 6D).complexes from the cell surface. The effect was main-
tained with longer IFNg-incubation times (at least for
7 weeks) but reverted as soon as 3 days after IFNg Mature Dendritic Cells Constitutively Express
the Immunoproteasome and Do Not Presentwithdrawal (data not shown). The IFNg treatment did
not affect the level of expression of RU1, as measured the RU1 Epitope
Given the ubiquitous expression of RU1, one may won-by RT±PCR (Figure 2A) and Western blot (Figure 2B).
The same effect was observed after IFNg treatment of der why anti-RU1 CTL are not deleted in the thymus
and how they remain inactive in the peripheral lympho-HLA-B51 allogeneic melanoma cell lines (Figure 6B). We
also verified that the prolonged exposure to IFNg did cyte pool without being activated by dendritic cells. A
possible explanation is that dendritic cells do not pre-not prevent the presentation of another peptide corre-
sponding to a mutated tumor antigen, thereby excluding sent the RU1 epitope. We therefore analyzed the type
of proteasome present in dendritic cells. We prepareda general defect in the capacity of the treated cells to
stimulate CTL (Figure 6C). dendritic cells from normal individuals by cultivating ad-
herent blood monocytes with GM-CSF and IL-4 for 7We purified proteasomes from BB64-RCC cells treated
(B) Main peptide fragments detected after 1 hr of digestion of the RU1 precursor peptide by proteasomes purified from the different cell
types. The epitope recognized by CTL 381/84 is boxed. The lines indicate the different fragments and their thickness is proportional to the
amount of each fragment.
(C) Kinetics of disappearance of the precursor peptide and of appearance of the main fragments, including antigenic fragment RU129-42.
Quantification of the peptides was performed by measuring the surface area of the relevant peaks on the UV chromatograms as outlined in
(D). Results are expressed as surface units measured on the UV trace (mV.s).
(D) Mode of quantitation of the fragments shown on (C) at the 1 hr digestion point. The digests were separated by HPLC and analyzed online
by UV spectrometry and electrospray ionization/mass spectrometry (ESI/MS). Peptide quantitation was provided by integration of the four
major peaks on the UV chromatogram (top row). These peaks eluted within the 25±32 min retention time range, which is shown enlarged in
the inserts. The corresponding ESI/MS data shown below indicated that these UV peaks correspond to the following fragments: peak 1,
peptide fragment RU129-44; peak 2, peptide fragment RU129-42; peak 3, peptide fragment RU129-39; and peak 4, precursor peptide RU129-47. The
first ESI/MS spectrum shows the total ion current (TIC) produced by all ions eluting at the different retention times. The predominant ion
present in each UV peak was determined from the m/z spectrum extracted from the TIC at the retention time corresponding to each UV peak
(inserts in the next four rows). Peak 1 contained ion m/z 834, which is the doubly charged peptide RU129-44; peak 2 contained ion m/z 726,
corresponding to the doubly charged peptide RU129-42; peak 3 contained ion m/z 1086, which is the singly charged peptide RU129-39; and peak
4 contained ion m/z 689, which is the triply charged precursor peptide RU129-47. These single m/z ions were then searched in the whole
chromatogram: the last four spectra display the ion current produced by each of them, and demonstrate that these ions elute exclusively at
the retention times corresponding to the relevant UV peaks. UV peak 2 elutes close to a contaminant peak (m/z corresponding to precursor
RU129-47 minus one valine), which was excluded from the quantitation (Ayyoub et al., 1998).
Results shown are representative of several experiments. Similar results were also obtained using a longer precursor peptide extended by
five residues at the N terminus.
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Figure 7. Presence of the Immunoproteasome in Dendritic Cells and
Lack of Activation of anti-RU1 CTL by Mature Dendritic Cells
(A) Dendritic cells were derived from adherent monocytes using
GM-CSF and IL-4. Immature dendritic cells were collected after 7
days or were induced to mature for 2 days by incubation with TNFa,
interleukin-1b, interleukin-6, and prostaglandin-E2. Fresh B lympho-
cytes were also collected. Proteasomes were purified from each
cell type by immunoprecipitation and tested for the presence of
LMP7 by Western blot. Staining of constitutive subunit a2 was per-
formed to control the amount of proteasomes loaded.
Figure 6. Loss of Recognition by CTL 381/84 of Cells Expressing (B) Immature and mature dendritic cells prepared from an HLA-B51
the Immunoproteasome donor were tested for recognition by anti-RU1 CTL 381/84 in a TNF
production assay. The dendritic cells pulsed for 30 min with the(A) BB64-RCC cells were treated with 100 U/ml of recombinant IFNg
RU1 antigenic peptide (1 mg/ml) and washed before addition of thefor 2, 4, or 6 days before being tested for recognition by CTL 381/
CTL were used as positive control (open bars). Similar results were84 in a TNF production assay. Fresh IFNg was added every 2 days
obtained with two different HLA-B51 donors. Results 6 SEM areand during the 20 hr incubation with the CTL for the TNF assay.
shown.(B) Allogeneic melanoma lines LB4-MEL and LB39-MEL were
treated with IFNg for 15 days and tested as above.
(C) BB64-RCC cells transfected with mutated gene KIAA0205, which cells prevented them from processing the RU1 peptide,codes for a mutated epitope presented by HLA-B44 to CTL 360b/
we prepared dendritic cells from HLA-B51 individuals40 (GueÂ guen et al., 1998), were treated for 9 days with IFNg and
and tested them for recognition by the anti-RU1 CTL.tested for recognition by both CTL clones.
(D) TNF released by CTL 381/84 after incubation with BB64-RCC As shown on Figure 7B, although immature dendritic
transfected with plasmid constructs encoding LMP2, LMP7, and cells were still capable of stimulating the CTL, mature
MECL1. As positive controls, the target cells were incubated with dendritic cells were totally unable to stimulate the CTL.
1 mg/ml of peptide VPYGSFKHV and washed before addition of the We verified by RT±PCR that gene RU1 was expressedCTL (open bars). Results 6 SEM are shown.
in both types of dendritic cells (Figure 2A). This result
therefore indicates that the peptide is not processed by
mature dendritic cells. The fact that immature dendriticdays as described previously (Romani et al., 1994; Sal-
lusto and Lanzavecchia, 1994). These immature den- cells can still activate the CTL could result either from
a residual expression of standard proteasome by thosedritic cells were then incubated for 2 days with TNFa, IL-1,
IL-6, and prostaglandin-E2 to induce their maturation cells, from remaining preexisting antigenic complexes,
or from the presence of a minority of other cells in the(Jonuleit et al., 1997). We performed a Western blot with
proteasomes purified from both immature and mature population.
dendritic cells (Figure 7A). Both proteasomes contained
LMP7, showing that dendritic cells constitutively ex- The Major Antigenic Peptide of Melanoma
Differentiation Antigen Melan-AMART1 Is Notpress the immunoproteasome, irrespective of their mat-
uration status. By contrast, proteasomes isolated from Processed by the Immunoproteasome
The lack of processing by the immunoproteasome isfresh B cells do not contain LMP7 (Figure 7A). To confirm
that the presence of the immunoproteasome in dendritic not unique to the RU1 epitope. We have initiated the
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analysis of ten other antigens by testing the recognition
by the relevant CTL of target cells treated for at least
1 week with IFNg. Four of them were still presented
efficiently after IFNg treatment; these were tumor-spe-
cific antigen RAGE-111-20 (Gaugler et al., 1996), two re-
cently identified mutated tumor epitopes, and a self-
antigen expressed in kidney and liver. Six antigens were
recognized less efficiently on the cells treated with IFNg.
These were tumor-specific antigens MAGE-A1161-9 and
MAGE-A3168-76 (Traversari et al., 1992a; Gaugler et al.,
1994), melanoma differentiation antigens Melan-A26-35
and gp100209-17 (Kawakami et al., 1994; Kawakami et al.,
1995), and two HLA-A2-restricted peptides derived from
ubiquitous proteins laminA/C and Na,K-ATPase (V. Bri-
chard and A. Van Pel, personal communication).
Figure 8A shows the loss of recognition after IFNg
treatment of the Melan-A and gp100 antigens presented
by HLA-A2, which are widely used as targets in clinical
trials of cancer immunotherapy (JaÈ ger et al., 1996a; Nes-
tle et al., 1998; Rosenberg et al., 1998). For gp100, the
loss of recognition was clearly not due to a lower level of
expression of the gene following IFNg treatment (Figure
8B). For Melan-A, the IFNg treatment of the melanoma
cells reduced the level of expression of the gene, but
in our view not enough to account for the complete loss
of CTL recognition (Figure 8B). Moreover, we demon-
strated that the immunoproteasome is incapable of gen-
erating the antigenic peptide Melan-A26-35 by analyzing
the digestion by both the standard proteasome and the
immunoproteasome of a synthetic peptide of 26 amino
acids encompassing the epitope. As shown in Figure
8C, the Melan-A26-35-specific CTL recognized the digests
obtained with the standard proteasome but not those
obtained with the immunoproteasome.
The loss of recognition of IFNg-treated cells by CTL
directed against the other epitopes mentioned above
may also be due to the lack of processing of those
epitopes by the immunoproteasome. However, we must
emphasize that, considering the pleiotropic effects of
IFNg, several other mechanisms could account for the
loss of CTL recognition.
Figure 8. Lack of Processing of Melanoma Differentiation Antigen
Melan-A26-35/HLA-A2 by the ImmunoproteasomeDiscussion
(A) Loss of CTL recognition of melanoma cells after prolonged treat-
ment with IFNg. Melanoma cells LB39-MEL and BB90-MEL wereWe show here that a number of antigenic peptides that
treated with 100 U/ml IFNg for 8 and 16 days, respectively, andare efficiently produced by the standard proteasome
tested for recognition by anti-Melan-A26-35/HLA-A2 CTL 246/15 andare not produced by the immunoproteasome. This con-
anti-gp100209-17/HLA-A2 CTL 446A/11. As positive controls, mela-tradicts the notion that the immunoproteasome is al- noma cells were pulsed with the relevant antigenic peptides (10 mg/
ways better suited for the processing of MHC class ml of peptide EAAGIGILTV for Melan-A and 2 mg/ml of peptide
I±restricted peptides. A major difference between the ITDQVPFSV for gp100) and washed prior to addition of the CTL
(open bars). The amount of TNF produced by CTL alone (7 pg/mltwo forms of proteasomes in terms of catalytic activity
for the anti-Melan-A CTL and 0 pg/ml for the anti-gp100 CTL) wasis the severely reduced ability of the immunoproteasome
subtracted from the experimental values. Results 6 SEM are shown.to cleave after acidic residues (unpublished data; Gac-
(B) RT±PCR analysis of Melan-A and gp100 expression in melanoma
zynska et al., 1993). This activity is mainly exerted by lines treated with IFNg or untreated. LB39-MEL was treated for 8
the b1 subunit, which is replaced by LMP2 in the immu- days with IFNg and BB90-MEL for 35 days.
noproteasome (Gaczynska et al., 1996). The b1 subunit (C) Recognition of proteasomal peptide digests by Melan-A26-35-spe-
cific CTL 246/15. The indicated precursor peptide corresponding tois also responsible for the cleavage after residues with
residues 15±40 of Melan-A and encompassing the epitope (boxed)branched side chains, such as valine (Dick et al., 1998;
was digested with the standard proteasomes isolated from BB64-Groll et al., 1999). As the RU1, Melan-A, and gp100
RCC cells (closed circles) or with the immunoproteasomes isolated
epitopes studied here all have a valine at their C termi- from IFNg-treated BB64-RCC cells (closed triangles). The digests
nus, the absence of the b1 subunit in the immunoprotea- obtained at different time points were pulsed onto HLA-A2-positive
some may explain our observations. Since a C-terminal NA8-MEL cells. CTL 246/15 was added and TNF production was
measured after 20 hr. Results 6 SEM are shown.valine is a commonly found motif in peptides associated,
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for example, with HLA-A2, this raises the interesting do not require proteasome digestion in dendritic cells,
possibility that the range of peptides presented by cer- than with proteins or full-length recombinant vectors.
tain HLA class I alleles may be particularly affected by
Experimental Proceduresthe presence of the immunoproteasome.
The presence of CTL directed against ubiquitous self-
Cell Linesantigens in the peripheral lymphocyte pool raises a num-
BB64-RCC was derived from the primary renal cell carcinoma ofber of questions: how do such T cells escape negative patient BB64. BB64-RCC and its transfected derivatives were cul-
selection in the thymus? And why do they not normally tured in DMEM supplemented with HEPES and glucose (Life Tech-
induce autoimmune damage in the periphery? Our re- nologies). 293-EBNA and the 293-EBNA-B51 transfectant were cul-
tured in DMEM. The lymphoblastoid cell line BB64-EBV was derivedsults showing that monocyte-derived dendritic cells
from the PBL of patient BB64 with 1 mg/ml cyclosporin and 20%carry immunoproteasomes and cannot present the RU1
(v/v) of supernatant of EBV-transformed B95-8 cells using standardepitope provide a plausible explanation. A high level of
techniques. This cell line was grown in RPMI 1640 medium (Lifeimmunoproteasome has been observed in the thymus
Technologies). Other cell lines were cultured in Iscove's medium
(Zanelli et al., 1993; Stohwasser et al., 1997). A subset (Life Technologies). The culture medium of LB2043-PTEC was sup-
of dendritic cells, probably of lymphoid origin, appears plemented with ACL-4 as described (Gazdar and Oie, 1986). All
to be responsible for the presentation of self-antigens media were supplemented with 10% FCS (Life Technologies) and
L-arginine (116 mg/ml), L-asparagine (36 mg/ml), L-glutamine (216to thymocytes for negative selection (ArdavõÁn, 1997;
mg/ml), streptomycin (0.1 mg/ml), and penicillin (200 U/ml). WhereAmsen and Kruisbeek, 1998). These thymic dendritic
indicated, the cell lines were cultured with 100 U/ml IFNg (R&Dcells could also contain predominantly immunoprotea-
Systems, Oxon, UK) renewed every other day. All stable transfec-
somes and would therefore allow the escape of RU1- tants were obtained by the calcium phosphate method (Traversari
specific CTL from negative selection. Such CTL precur- et al., 1992b). BB64-RCC were stably transfected with either the B7-1
sors could circulate in the peripheral lymphocyte pool molecule (BB64-RCC-B7) or the mutKIAA0205 cDNA as previously
described (GueÂ guen et al., 1998). 293-EBNA cells were transfectedwithout undergoing autoimmune activation despite the
with HLA-B*5101 cloned into pcDNA3.1/Zeo (Invitrogen), selectedpresence of the antigen on most cells, again because
with 600 mg/ml Zeocin (Invitrogen), and cloned by limiting dilution.of lack of processing by dendritic cells, which are con-
The LMP2.1, LMP7-E2.1, and MECL1 cDNAs were obtained by PCRsidered as the major antigen-presenting cells capable
amplification of cDNA from BB64-EBV cells, using as sense and
of activating naive T cells. It is unclear whether macro- antisense primers 59-GTGCCTTGCAGGGATGCT and 59-AGAAA
phages can also activate naive T cells, but this should GAGAAGTCTGGGGAAG for LMP2, 59-TCATGGCGCTACTAGAT
at least require their prior activation with IFNg, and GTATGC and 59-ACTCTCTCTTTGGCTCAGGC for LMP7-E2, and
59-TCTGACCGACTCATCCGC and 59-TTGTTCCAAGCTCTAAGCCTCthey would therefore also contain immunoproteasomes
for MECL1. The LMP2 cDNA was cloned into pcDNA3.1/Zeo, LMP7-(Freedman et al., 1991; Yoshida et al., 1994). A study
E2 was cloned into pEF-BOSpuro-PL3 (GueÂ guen et al., 1998), andinvolving many antigens will be required to determine
MECL1 was cloned into pEF/myc/cyto (Invitrogen). BB64-RCC cells
to what extent this scheme explains the presence of were first transfected with equal amounts of the LMP2 and MECL1
peripheral T cells that can be activated against ubiqui- constructs and selected with 60 mg/ml bleocin (Calbiochem) and 4
tous self-antigens. mg/ml G418 (Life Technologies). Resistant cells were then further
transfected with the LMP7 construct, selected with 0.6 mg/ml puro-One may wonder how RU1-specific CTL were derived
mycin (Sigma), and cloned by limiting dilution.in vitro despite the lack of presentation of the RU1 pep-
tide by professional antigen-presenting cells. One inter-
CTL Clonespretation is that this resulted from the use of B7-1-trans-
CD8-positive lymphocytes of patient BB64 were sorted from blood
fected tumor cells to stimulate the lymphocytes in the mononuclear cells (PBL) with magnetic beads (Miltenyi Biotec, Ber-
presence of exogenous IL-2, IL-6, and IL-12. By doing gisch-Gladbach, Germany) and an autologous mixed lymphocyte-
so, we probably transformed the tumor cells, which con- tumor cell culture (MLTC) was performed by mixing these lympho-
cytes with irradiated BB64-RCC-B7. IL-6 (106 U/ml) and IL-12 (10tain the standard proteasome, into efficient antigen-pre-
ng/ml) were added to the MLTC during the first week, and IL-2 (10senting cells.
U/ml) and IL-7 (5 ng/ml) were added during the second week. AtThe observation that some melanoma differentiation
day 13, lymphocytes were cloned by limiting dilution in Iscove'santigens that are used for antitumoral vaccination are
medium supplemented with 10% human serum and IL-2 (50 U/ml).
also poorly processed by the immunoproteasome has The long-term culture was conducted as described previously (HeÂ rin
implications for tumor immunotherapy. An IFNg-rich en- et al., 1987). CTL 446A/11 and 246/15 were obtained from autolo-
vironment, such as that found in a lymph node or a gous MLTC performed using PBL and the irradiated tumor cells of
melanoma patients BB90 and LB373, respectively, as describedtumor mass heavily infiltrated with T cells, could cause
previously (HeÂ rin et al., 1987). The lytic activity of the CTL was testeda proteasome switch in the tumor cells, resulting in a
in chromium release assays as described previously (Boon et al.,lack of presentation of certain tumor antigens and es-
1980).cape from CTL attack. This could explain why tumor
cells can coexist with activated CTL in invaded lymph CTL Stimulation Assay
nodes from melanoma patients (Romero et al., 1998). Target cells (2500±5000) were incubated with 2±3000 CTL in 100 ml
This tumor escape mechanism could also be favored culture medium supplemented with 25 U/ml IL-2. Where indicated,
by systemic IFNg treatment and could account for some target cells were incubated for 30 min at 378C with the relevant
antigenic peptide and washed with medium before addition of theobservations of increased tumor progression after such
CTL. Proteasomal digestions were resuspended in 200 ml X-vivo 10treatment (Kowalzick et al., 1990; Meyskens et al., 1990).
medium (Whittaker Bioproducts). Fifty microliters were pulsed onThe lack of immunoproteasome processing of some
30000 293-EBNA-B51 (RU1 digests) or NA8-MEL (Melan-A digests)
melanoma antigens should also be considered in the cells for 30 min at 378C prior to the addition of CTL. The supernatants
design of cancer vaccines. For such antigens, better were collected after 20 hr and their TNF content was determined
CTL responses should be induced with immunogens by testing their cytotoxic effect on WEHI-164 clone 13 (Traversari
et al., 1992b; Espevik and Nissen-Meyer, 1986).such as peptides or peptide-encoding minigenes, which
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Cloning of the HLA-B51 cDNA from BB64-RCC quantified using an ELISA. Ninety-six-well plates were coated with
The HLA-B cDNA were amplified from total RNA of BB64-RCC as duplicate serial dilutions of the proteasome preparations. After
described previously (GueÂ guen et al., 1998) using forward primer blocking and extensive washing, 3 mg/ml purified and biotinylated
59-CGGGATCCGCCGAGATGCGGGTCAC, which is specific for the polyclonal anti-proteasome antibody was added to the wells. The
59-untranslated region of most HLA-B, and cloned into pcDNA3 reaction was further incubated with streptavidin-HRP conjugate
(Invitrogen). One HLA-B51 clone was sequenced and found to be (Life Technologies) and was revealed by adding OPD (o-Phenylene-
the allelic subtype B*5101. diamine dihydrochloride; Sigma). The proteasome amounts of the
various cell lines were compared on the basis of values situated in
Cloning of the RU1 cDNA the linear range of the titration curve.
A cDNA library prepared with RNA from BB64-RCC cells was cloned
into plasmid pCEP4 (Invitrogen) as described previously (GueÂ guen Peptide Digestions and Mass Spectrometry
et al., 1998). DNA from this library was transfected into 293-EBNA Four micrograms of purified proteasomes were used to digest 5.4
cells, along with a plasmid construct encoding HLA-B*5101, as de- mg peptide in 10 ml of 10 mM Tris-HCl (pH 8) at 378C. Digestion was
scribed previously (GueÂ guen et al., 1998). Transfected cells were stopped either by adding 2 ml trifluoroacetic acid (TFA) 10% (RU1
screened for recognition by CTL 381/84 using the CTL stimulation digests) or by freezing (Melan-A digests). Peptides were separated
assay described above. The cDNA clone obtained was not complete on a Brownlee Aquapore C18 column (2.1 mm 3 10 cm) at a flow
at the 39 end, and the missing sequence was obtained by 39-RACE rate of 200 ml/min. The separation was achieved with a gradient
PCR (Life Technologies). elution of 10%±45% B for 35 min (A is 0.08% TFA and B is 50/50/
0.08 CH3CN/H2O/TFA v/v/v). UV absorption was measured at 215
Transient Transfection nm, online with the mass spectrometric detection performed on a
Transient transfection of the normal kidney cell line LB2043-PTEC Finnigan TSQ700 triple quadrupole mass spectrometer (Finnigan-
was performed with the DMRIE-C reagent (Life Technologies). Mat) equipped with an electrospray source. Mass spectra were
Briefly, 10,000 cells were plated in flat-bottom microwells and trans- obtained by scanning the range of masses corresponding to m/z
fected with 150 ng of plasmid pcDNA3 containing the HLA-B*5101 values between 300 and 1900 every 3 s and allowed peptide identifi-
cDNA and 0.25 ml DMRIE-C. Transfected cells were tested in CTL cation. Peptide quantitation was then obtained from the UV trace
stimulation assay 20 hr after transfection.
by measuring corresponding peak areas.
RT±PCR Analysis of the Expression of RU1, Melan-A,
Preparation of Dendritic Cellsand gp100 mRNA
Dendritic cells were derived from adherent monocytes as describedTotal and poly(A)1 RNA were extracted as described previously
(Romani et al., 1994; Sallusto and Lanzavecchia 1994), using GM-(GueÂ guen et al., 1998), except the human thymus poly(A)1 RNA,
CSF (70 ng/ml) and IL-4 (200 U/ml). Immature dendritic cells werewhich was purchased from Clontech, and the poly(A)1 RNA from
collected after 7 days or were induced to mature for 2 days bythe dendritic cells, which was extracted using the ªmRNA isolation
incubation with TNFa (10 ng/ml), IL-1b (10 ng/ml), IL-6 (1000 U/ml),kit for blood/bone marrowº (Boehringer Mannheim, Mannheim, Ger-
and prostaglandin-E2 (1 mg/ml) (Jonuleit et al., 1997). Fresh B lym-many). Reverse transcription was performed as described pre-
phocytes were also collected.viously (GueÂ guen et al., 1998). PCR conditions were optimized to
allow a quantitative amplification of the RU1, Melan-A, gp100, and
b-actin cDNA, as demonstrated by PCR products whose intensity Immunoprecipitation and Detection of Proteasome Subunits
decreased with dilution of the template cDNA. Quantitative PCR Three million cells were lysed in 1 ml lysis buffer (20 mM Tris-HCl
amplification of the RU1 cDNA was performed with the Expand [pH 7.6], 150 mM NaCl, 5 mM EDTA, 1% Nonidet NP-40) for 10 min
Long Template PCR System (Boehringer) using buffer 3 and pri- on ice. Unsolubilized material was removed by centrifugation at
mers SMO18 (59-TTGGACCCGTGGATACCC) (sense) and SMO19 13000 3 g for 10 min at 48C. Cleared lysate was split in equal aliquots
(59-CATCAGTAACAATCCAAGTGC) (antisense). PCR conditions and each aliquot was incubated with 5 mg purified monoclonal anti-
were 5 min at 948C followed by 30 cycles consisting of 1 min at body MCP-21 (ECACC, Salsburry, UK) and 20 mml protein G sepha-
948C, 2 min at 658C and 3 min at 728C, and a final extension of 15 rose slurry (1:1 in lysis buffer; Pierce) for 45 min at 48C under rotary
min at 728C. Melan-A and gp100 mRNA were quantified as described shaking. The immunoprecipitates were washed three times with
previously (Brasseur et al., 1995), except for gp100, where 21 cycles lysis buffer containing 0.1% SDS, resuspended in 20 ml SDS sample
were performed with an elongation temperature of 648C (JaÈ ger et buffer (Valmori et al., 1999), and boiled at 1008C for 3 min. The
al., 1996b). The b-actin mRNA was amplified in each sample to samples were subjected to SDS-12% PAGE followed by transfer
check the amount and integrity of the RNAs (De Plaen et al., 1997). onto nitrocellulose membranes. Membranes were soaked overnight
PCR products were analyzed on 1% agarose gels stained with ethid- in PBS/2% non-fat milk, washed, and incubated for 60 min in tissue
ium bromide. culture medium containing 10% fetal calf serum and either 1 mg/ml
mouse monoclonal anti-a2 (C3) antibody MCP-21, rabbit polyclonal
Detection of the RU1 Protein by Western blot anti-LMP2 (1:1000; Affinity Ltd, Exeter, UK), or anti-LMP7 (1:2000;
A polyclonal antiserum was generated by immunizing rabbits with a Affinity Ltd). Membranes were extensively washed in PBS/0.5%
C-terminal fragment of the RU1 protein coupled to KLH (Eurogentec, Tween-20 before horseradish peroxidase±conjugated monoclonal
Belgium). Two million cells were lysed in 200 ml 1.25 X Laemmli anti-mouse or anti-rabbit antibody (both 1:5000 [Amersham]) was
buffer (Tris 78 mM, 12.5% glycerol, and 1.8% SDS) and cell debris
added. Membranes were further incubated for 45 min in PBS/2%
were removed by centrifugation. The protein content of the cell
non-fat milk, extensively washed, and revealed with the ECL solu-
lysates was determined by the BCA Protein Assay (Pierce). After
tions (Amersham).addition of 2% (v/v) b-mercaptoethanol and bromophenol blue and
incubation for 3 min at 1008C, equal amounts of total proteins were
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